Llwytho...
Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | JAMA Cardiol |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Medical Association
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5815006/ https://ncbi.nlm.nih.gov/pubmed/28903137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3051 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|